Product Information
WEGOVY 2.4 MG/0.75 ML PEN is a brand product labeled by Novo Nordisk, priced at $435.5263 per ML under NDC 00169452414. Its NADAC has been published 263 times since Sep 22, 2021.
FDA first approved this application on Jun 4, 2021.
Strength
2.4 mg/.75mL
Manufacturer
Novo NordiskNDC
00169452414
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SEMAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA215256FDA Approved
6/4/2021
On Market Since
6/5/2021
Pharmacological Classes
Price Statistics
The NADAC for WEGOVY 2.4 MG/0.75 ML PEN has been published 263 times since Sep 22, 2021, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $435.5263 per ML |
|---|---|
| All-time high | $435.5729 (Aug 12, 2026) |
| All-time low | $431.7439 (May 17, 2023) |
| 52-week high | $435.5729 |
| 52-week low | $434.9989 |
| Median price | $433.8893 |
| Average price | $433.4829 |
| Largest weekly change | -0.5% (Jul 20, 2022) |
| Weeks tracked | 263 |
| Tracking since | Sep 22, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the semaglutide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
semaglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of WEGOVY 2.4 MG/0.75 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for WEGOVY 2.4 MG/0.75 ML PEN, manufactured by Novo Nordisk, is $435.5263 per ML (NDC 00169452414), effective Sep 30, 2026.
How has the price of WEGOVY 2.4 MG/0.75 ML PEN changed over time?
Over the history we have for it, the NADAC for WEGOVY 2.4 MG/0.75 ML PEN has held within roughly two percent of its current level. It has been tracked across 263 weekly CMS publications since Sep 22, 2021.
What are the highest and lowest recorded NADAC prices for WEGOVY 2.4 MG/0.75 ML PEN?
Since Sep 22, 2021, the NADAC for WEGOVY 2.4 MG/0.75 ML PEN has ranged from a low of $431.7439 (May 17, 2023) to a high of $435.5729 (Aug 12, 2026), with a median of $433.8893 per ML.
Are there cheaper alternatives to WEGOVY 2.4 MG/0.75 ML PEN?
No other NADAC-published product currently shares the active ingredient and strength of WEGOVY 2.4 MG/0.75 ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures WEGOVY 2.4 MG/0.75 ML PEN?
WEGOVY 2.4 MG/0.75 ML PEN (NDC 00169452414) is labeled by Novo Nordisk, and CMS classifies it as a brand product.